Second-Line Antiandrogen Therapy in Japanese Men with Advanced Prostate Cancer Relapsed after Primary Combined Androgen Blockade: Who Will Benefit from Second-Line Hormonal Therapy?

Publisher： Karger

E-ISSN： 1423-0399|85|4|491-497

ISSN： 0042-1138

Source： Urologia Internationalis, Vol.85, Iss.4, 2010-08, pp. : 491-497

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Docetaxel: Efficacy in First- and Second-Line Therapy of Advanced Breast Cancer

By  

Oncology Research and Treatment, Vol. 23, Iss. 6, 2004-11 ,pp. : 1-3

Karger

Access to resources Recommend Favorite

Irinotecan in Second-Line Therapy of Metastatic Colorectal Cancer

By  

Oncology Research and Treatment, Vol. 23, Iss. 4, 2000-05 ,pp. : 15-17

Karger

Access to resources Recommend Favorite

Second-Line Chemotherapy of Advanced Disseminated Gastric Cancer after Cisplatin, Infusional 5-Fluorouracil, Folinic Acid (PLF): Benefit Dependant on Progression-Free Interval after First-Line Therapy

By  

Oncology Research and Treatment, Vol. 28, Iss. 10, 2005-09 ,pp. : 499-502

Karger

Access to resources Recommend Favorite

Selection of a Patient Subgroup with Advanced Esophageal Squamous Carcinoma Who Could Benefit from Second-Line Chemotherapy

By  

Oncology, Vol. 79, Iss. 5-6, 2011-03 ,pp. : 363-369

Karger

Access to resources Recommend Favorite

PSA and Second-Line Therapy of Hormone Refractory Prostate Carcinoma

By  

Urologia Internationalis, Vol. 66, Iss. 3, 2001-04 ,pp. : 131-134

Karger

Access to resources Recommend Favorite